Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Jean Baptiste Briere"'
Publikováno v:
Journal of Market Access & Health Policy, Vol 11, Iss 1 (2023)
ABSTRACTBackground: Heart failure is a chronic disease linked with significant morbidity and mortality, and uncontrolled resting heart rate is a risk factor for adverse outcomes. This systematic literature review aimed to assess the efficacy, safety,
Externí odkaz:
https://doaj.org/article/b377d15c271a40acaef6de0020c11c55
Autor:
Ken Okumura, Hiroshi Inoue, Masahiro Yasaka, Juan Marcos Gonzalez, A. Brett Hauber, Bennett Levitan, Zhong Yuan, Jean Baptiste Briere
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 2, Iss 2 (2015)
**Background:** Anticoagulants are recommended for stroke prevention in patients with atrial fibrillation (AF), but are associated with an increased risk of bleeding; therefore, physicians face benefit-risk tradeoffs when prescribing anticoagulants t
Externí odkaz:
https://doaj.org/article/1a7dff498d2342aca8b03225fec1ab23
Autor:
Pierre Levy, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin, Jean-Baptiste Briere
Publikováno v:
Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019)
Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treatment in NV
Externí odkaz:
https://doaj.org/article/36db1862bbdc4647977d929223085b73
Autor:
Laura Portas, Rupert Bauersachs, Kevin Bowrin, Jean-Baptiste Briere, Alexander Cohen, Maria Huelsebeck, Schuyler Jones, Jennifer K Quint
Publikováno v:
Vascular medicine (London, England). 27(5)
Background: Symptoms, severity, and acuteness of peripheral artery disease (PAD) are major determinants of severe limb symptoms, subsequent risk of cardiovascular events, and mortality. Lower-extremity revascularization (LER) is a key option to relie
Autor:
Kevin Bowrin, Aurélie Millier, Jean-Baptiste Briere, B. Verheggen, M. Coppens, S. Tempelaar, J. A. Spoorendonk
Publikováno v:
Journal of medical economics, 24(1), 1231-1239. Taylor and Francis Ltd.
Background: Patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD) are at substantial risk of atherothrombotic events. The COMPASS trial showed that patients with stable CAD or PAD experienced significant benefits after
Publikováno v:
Journal of Medical Economics
Journal of Medical Economics, 2020, 23 (10), ⟨10.1080/13696998.2020.1792917⟩
Journal of Medical Economics, 2020, 23 (10), ⟨10.1080/13696998.2020.1792917⟩
Real-world evidence (RWE) provides external validity, supplementing and enhancing the randomized controlled trial data with valuable information on patient behaviors and outcomes, turning efficacy and safety results into real-world effectiveness and
Autor:
Janita Balradj, Kevin Bowrin, Marc Schindewolf, Maria Huelsebeck, Jean-Baptiste Briere, Jan Beyer-Westendorf
Publikováno v:
Angiology. 71:773-790
A systematic literature review was conducted to identify and summarize the clinical efficacy and safety of available antithrombotic therapies after peripheral endovascular or surgical revascularization in patients with peripheral artery disease (PAD)
Autor:
Outi Virtanen, Erkki Soini, Saku Väätäinen, Kevin Bowrin, Jean-Baptiste Briere, Aurélie Millier
Publikováno v:
Advances in Therapy
Introduction Currently, 15–20% of individuals with coronary artery disease (chronic coronary syndrome [CCS]) or peripheral artery disease (PAD) receiving routine treatment experience cardiovascular events (CVEs) within 3–4 years. Using PICOSTEPS
Autor:
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere
Aims A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc91d72161fa9c186b9b5995d9975a73
http://hdl.handle.net/10230/55059
http://hdl.handle.net/10230/55059
Autor:
Jean-Baptiste Briere, Mark R. Nehler, Janita Balradj, Kevin Bowrin, Sebastian Debus, Maria Huelsebeck, Rupert Bauersachs
Publikováno v:
Angiology. 71:303-314
Patients with peripheral artery disease (PAD) have an increased risk of cardiovascular (CV) and limb events, but the disease is frequently underdiagnosed and treatment options are limited. This review examines the disease burden of symptomatic PAD as